Invesco Global High Yield CorporateBond ESG UCITS (GBHE) ニュース

Get ready to be thrown under (FNMA) bus .
No way no how slick suit and haircut Wall Street huckster gives one cent care about hopeful investor. More than likely common share holder has been ginned up . Sheep ready for slaughter or should I say vultures .

tangerine Mussolini
Killing the market
layoffs all over
tariff news has not yet brought in long term sellers
market should be up sunday nite NOPE

Lol!! I want profits!! What you want helps me in no way!!
Exactly. Because the truth with documentation that BCAP is a scam and Jake P. Noch is a serial scammer prevents scamming pumpers and liars like you from making profits by creating bagholders here. And that's part of my goal - and to h

What do you expect and how can you back your thoughts? Thanks

I mean Kim said once they hit 1.5 metric tons they're open for business and they're about halfway there so..... You're a genius! Congrats on the business. I also run one with 100% positive feedback over 22 years so I get the perspective🤪

Also, in my Arby's voice "I have the

We've invested similarly

Glenn Miller’s still missing, and Emil Malak and Rich Inza are still crooks.

Marc loved your ides

I usually enjoy a beer with my pizza...........I would like to know what's in the Kool Aid........

Here we are on the cusp of the Monsta $FMCC~ $FNMA~ Gains we've all been waiting for doin da Heebie Jeebie Dance, 😃😄😁😆😅😂!
[yt]MUB3ZR4F8vw?si=Z3oB5zc_RHMtCGEY[/yt]

In my opinion, there will likely be significant pressure on the share price leading up to the conference call. A sell-off could occur the day before, with the stock potentially bottoming out by the end of the investor call. I could be wrong, but I've seen similar patterns many times over the past 25

GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

This is DUE DILIGENCE! Thank you Free Fannie.

https://x.com/freefannie/status/1878655047715991552?s=46&t=2Y42DPZFgRdwTBHj5W8jMQ

That Xeriant PR excellently written with bullshit:

""After successfully completing 75% of the demanding NFPA 286 test," meaning = "after failing the NFPA 286 test by missing 25% of the approval target testing requirement,"

"the Company used the data to make several key

You were actually partially right....BMXI has filed some SEC documents, some necessary (Form 1-A), some unnecessary (Form 4). And they do summarize a lot of the stuff that I think are fabrications....their production, mining operations, etc. Time will tell, but I think a lot of it (and probably

Jim wrote a blurb about seeking more US business.

Help you out any? 🤨

Any news or updates?

.0915 by Thursday.......